Advertisement

Topics

Oragenics, Inc. Announces Pricing of $12 Million Underwritten Public Offering

08:16 EDT 13 Jul 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the “Company”) today announced the pricing of an underwritten public offering of units for gross proceeds of $12 million, prior to deducting un...

Other Sources for this Article

Oragenics, Inc.
Corporate:
Michael Sullivan, 813-286-7900
Chief Financial Officer
msullivan@oragenics.com
or
Investor/Media Relations:
The Ruth Group
Tram Bui, 646-536-7035
tbui@theruthgroup.com

NEXT ARTICLE

More From BioPortfolio on "Oragenics, Inc. Announces Pricing of $12 Million Underwritten Public Offering"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...